TcBuster™ Non-viral Gene Delivery System for Cell and Gene Therapy

TcBuster™ non-viral gene delivery system for cell and gene therapy


Gene editing without the viral vector baggage.

TcBuster non-viral genetic delivery system and gene editing services solve the supply chain and timeline bottlenecks facing viral vector-based editing while maintaining high insertion efficiency and a low-risk profile. Proven to insert CAR and TCR constructs reliably and cost-effectively into T cells and NK cells, TcBuster is the future of genetically engineered autologous and allogeneic cell therapies. ScaleReady offers gene editing services in partnership with Bio-Techne.

Talk to an Expert

How does TcBuster gene delivery work?

TcBuster integrates your gene of interest (GOI) into host cell DNA using the highly efficient Red Flour Beetle transposase and specifically-designed transposons. Transposon gene editing systems have the safest insertion profile of any commercial gene delivery platform, with limited off-target effects and stable, reliable gene expression.

Watch Video

Insert large CAR payloads and maintain high efficiency.

TcBuster is advancing TCR and CAR-T engineering by accommodating insertion of large and multi-gene constructs. This allows you to create innovative, highly targeted, and controlled gene-modified immune cell therapies. Using optimized protocols, TcBuster transposition efficiency even outperforms lentivirus transduction.

Learn More...
TcBuster transposon gene editing comparison to Lentivirus transduction

CAR and TCR gene transfer without the viral vector baggage.

TcBuster addresses the cost, scalability, and integration challenges of retroviral and lentiviral vectors, as demonstrated in the table below. Manufacturing of TcBuster plasmids is inherently faster and less variable than retro and lentiviral production creating a more secure supply chain to support your gene edited immune cell therapies.


> Learn More

G-Rex expansion of CAR-T Cells following TcBuster transposon gene editing.

Scalable gene editing to support cell therapy manufacturing.

TcBuster gene edited immune cells are compatible with cell expansion in closed-system G-Rex bioreactors. Optimized transposition and expansion protocols will support research and therapeutic scales.

>Download the Brochure

TcBuster gene editing service options

From proof-of-concept studies and process optimization to GMP cell line manufacturing or technology licensing, we have you covered. We’ve partnered with Bio-Techne’s process development to make sure TcBuster integrates seamlessly into your clinical manufacturing process.

Contact a gene-editing specialist at ScaleReady using the form below >>

Additional TcBuster resources

TcBuster Non-viral Genetic Engineering Flyer

TcBuster non-viral gene editing solves the bottlenecks facing viral vector-based editing, including supply chain, manufacturing time, and integration safety. In this flyer:
  • How TcBuster works
  • Comparison to viral tranduction
  • Data on transposition efficiency and scalability

TcBuster Non-Viral Gene Engineering FAQ

The benefits of non-viral gene engineering, when compared with its viral counterpart, offer simplicity, and streamlined capabilities all while lowering risk and cost. TcBuster as part of the ScaleReady portfolio empowers cell therapy programs to move to market faster and with superior scalability ensuring confidence in reproducibility, bench to bedside.

See how TcBuster fits into the ScaleReady™ workflow.